A phase 1b study of isatuximab plus pomalidomide/dexamethasone in relapsed/refractory multiple myeloma

This phase 1b dose-escalation study evaluated isatuximab plus pomalidomide/dexamethasone in patients with relapsed/refractory multiple myeloma (RRMM). Patients who had received ≥2 prior MM therapies, including lenalidomide and a proteasome inhibitor (PI), were enrolled and received isatuximab at 5,...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:Blood
Main Authors: Mikhael, Joseph, Richardson, Paul, Usmani, Saad Z., Raje, Noopur, Bensinger, William, Karanes, Chatchada, Campana, Frank, Kanagavel, Dheepak, Dubin, Franck, Liu, Qianying, Semiond, Dorothée, Anderson, Kenneth
Format: Artigo
Sprog:Inglês
Udgivet: American Society of Hematology 2019
Fag:
Clinical Trials and Observations
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC6659612/
https://ncbi.nlm.nih.gov/pubmed/30862646
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2019-02-895193
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker